

1 **Application of hybrid failure mode effect analysis based on fuzzy AHP and**
2 **fuzzy TOPSIS in quality risk assessment of fixed-dose artemether-**
3 **lumefantrine tablets**

4 Salim Ilyasu^{a*}, Sani Malami^b, Garba Mohammed Khalid^c, Umar Sharif
5 Abdussalam^b, Abubakar Magaji Dawud^d, Mohammed Saratu^d, Al-Kasim Rabi
6 Falalu^d, Mustapha Fatima Zaharadeen^d, Farouq Idris Sani^d, Abdussalam Yayo
7 Manu^e, Ibrahim Adamu Yakasai^f, Basheer Abba-Zubair Chedi^b, Aminu Sahalu
8 Bello^e, Adam Bashir Ibrahim^a, Saadatu Julde^b, Maryam Shehu Idris^g, Lawal
9 Alhassan Bichi^b

10 ^aDepartment of Pharmaceutics and Pharmaceutical Technology, Bayero University, Kano,
11 Nigeria; ^bDepartment of Pharmacology and Therapeutics, Bayero University, Kano, Nigeria;
12 ^cDepartment of Pharmaceutics, University College London, London, United Kingdom; ^dFaculty
13 of Pharmaceutical Sciences, Bayero University, Kano; ^eDepartment of Medical Microbiology
14 and Parasitology, Bayero University, PMB 3011, Kano, Nigeria; ^fDepartment of Pharmaceutical
15 and Medicinal Chemistry, Bayero University, PMB 3011, Kano, Nigeria; ^g School of
16 Environmental and Life Sciences, University of Salford, United Kingdom

17 *Corresponding author Email: silyasu.pht@buk.edu.ng

18 **Abstract**

19 **Background:** A hybrid Failure Mode Effect Analysis (FMEA) based on fuzzy
20 logic and multicriteria decision analytics was applied as a post-marketing
21 surveillance tool for troubleshooting potential quality problems of Artemisinin
22 Combination Therapies (ACTs) as a means of aggregating subjective opinions of
23 quality experts in providing vital information for continuous management and
24 improvement of safety and quality standards.

25 **Research design and methods:** An FMEA team of five cross-functional quality
26 experts implemented a hybrid fuzzy FMEA model based on Analytical Hierarchy
27 Process (AHP) and Technique for Order of Preference by Similarity to Ideal
28 Solution (TOPSIS) to solve multicriteria decision problems in quality risk analysis
29 of historic quality control data of ACTs.

30 **Results:** Expert opinions were captured as triangular fuzzy numbers to represent
31 the linguistic scoring of risk-determining variables for fifteen failure modes. The
32 fuzzy AHP enabled systematic ranking of the variables, while the fuzzy TOPSIS
33 algorithm provided easily understood and configurable computational procedures
34 for ranking the failure modes based on optimal geometric paths to positive and
35 negative ideal solutions.

36 **Conclusions:** The quality risk of ACTs could be reliably established using the
37 fuzzy FMEA where aggregated experts' decisions and risk variables' weights are of
38 considerable importance to the final ranking of quality failures.

39 **Keywords:** artemisinin-based combination therapy; pharmaceutical quality
40 systems; quality risk management; FMEA; fuzzy logic; fuzzy TOPSIS; analytical
41 hierarchy process; health informatics

42 **Introduction**

43 Recent statistics published in the World Malaria Report have indicated that malaria remains
44 endemic in Nigeria as it disproportionately bears an alarming 31.3% of the global burden of the
45 disease [1]. Artemisinin-based combination therapy (ACTs) forms a principal component of
46 World Health Organization (WHO) recommended malaria treatment regimens [2]. Safe and
47 effective malaria prevention and eradication programmes strongly depend on the standards in the
48 quality of ACTs [2]. The term quality is a broad term that summarizes multi-attribute criteria
49 used to gauge the compliance level of the ACTs to fitness for intended clinical application

50 throughout its lifecycle. ACTs critical product attributes include the drug's identification, purity,
51 potency, shelf-life, dissolution kinetics, bioequivalence, disintegration, and compliance with
52 labelling and packaging requirements, in addition to several other pharmacopoeial and regional
53 regulatory specification [3–6]. The quality of ACTs is essential to both patient safety during the
54 use of the product and successful therapy.

55 Unfortunately, forensic analysis has revealed the structural vulnerability of the
56 pharmaceutical supply chain (both formal and informal) of Low and Middle-income Countries
57 (LMICs) to counterfeit and substandard ACTs posing significant public health risks [3,7,8]. The
58 presence of low-quality ACTs greatly jeopardizes the standards of the supply chain resulting in
59 diminished confidence in the healthcare systems [8]. Scientific evidence has shown that a
60 compromised drug distribution system is a major setback with negative disruptive tendencies
61 toward multifocal efforts in the fight against malaria in endemic regions. The proliferation of
62 substandard and counterfeit ACTs is deemed economic sabotage that propels significant risks to
63 parasite resistance, therapeutic failure, undesirable side effects, and even death [7,9].

64 An integrated approach to pharmaceutical product quality management is implemented
65 through a standardised pharmaceutical quality system that is applicable throughout the product's
66 lifespan with a targeted goal of assuring patient safety and achieving therapeutic goals. Within
67 the current regulatory thinking, as contextualized in the International Council on Harmonization
68 guidelines (ICHQ9 and ICHQ10) quality risk assessment is indicated to ascertain compliance
69 with the safety and efficacy standards of medicines throughout their lifecycle [10]. Accordingly,
70 implementing the ICH Q9 principles in the antimalarial products supply chain assures continuous
71 quality and process improvement plans with the ultimate goal of mitigating quality-dependent
72 public health risks [11–13].

73 *Failure mode effect analysis*

74 Failure mode effect analysis (FMEA) is a WHO-recommended quality risk assessment tool that
75 is used in the quantitative or qualitative assessment of product, process, or system risks by
76 linking the probability of occurrence (O) of fault (failure) with the severity (S) of the
77 consequences of such fault, and its detectability (D) [14]. Since ICH Q9 guidelines have
78 underscored the protection of patients by deploying a quality risk evaluation strategy [14], the
79 derived quality risk information is crucial as it proffers an avenue for critical decision-making by
80 regulators, industries, and all stakeholders in the ACT supply chain.

81 In the context of ACT quality risk assessment, the quality failure types that may potentially
82 affect the ACT performance and ability to meet the desired target quality product profile to
83 effectively treat malaria are assessed using the risk factors O, S, and D. In practice, for each
84 failure mode, the scores of S, O, and D are rated by the cross-functional FMEA team members
85 based on established FMEA risk factor scales [15,16]. A risk priority number (R.P.N) is then
86 mathematically calculated as a simple product of the risk factors according to Equation 1, and the
87 failure modes are prioritized in descending magnitude of the risk scores [4,13,17].

$$88 \quad R.P.N = O.S.D \quad (1)$$

89 Thus, for an ACT product with k failure modes (FM), corrective actions and risk mitigation plans
90 are proportionated based on hierarchy. Thus, FMEA troubleshoots non-conformances with
91 critical quality requirements. Although this traditional FMEA (tFMEA) is simple to implement
92 from a methodological context, it has been widely criticized for several cogent reasons [18,19].
93 Firstly, the risk factors' weights are accorded equal importance, while in a practical sense, the
94 inherent risk associated with each factor differs [16]. Consequently, equal R.P.N is often
95 obtained for different values of the risk factors, confusing failure prioritization. Consider failure

96 modes FM1, FM2, and FM3, each with (O, S, D) scores of (4, 7, 8), (4, 8, 7), and (8,7,4),
97 respectively. Each of the failure modes would result in an RPN score of 224 resulting in non-
98 discernible risks when Equation 1 is applied [18,19]. Thus, Equation 1 is itself mathematically
99 controversial. Therefore, the reliability of the prioritized failure modes is also questionable. The
100 implication of this is that failures that ought to have received the utmost corrective attention
101 might become erroneously neglected or undetected, and the whole objective of the FMEA is
102 defeated or compromised.

103 Another limitation of the tFMEA is that the use of crips values to represent various ratings of the
104 risk factors does not adequately recapitulate human reasoning and natural decision-making
105 culture. Human decisions are vague, and imprecise, albeit complete [20–22]. For instance, in
106 rating the likelihood of occurrence of a failure mode, according to the crips value 5 to denote
107 ‘moderate failure’ is not concordant with logical representation of human thinking and
108 judgement [22,23]. Hence, crips values were considered insufficient in assignment of risk scores
109 by FMEA decision team [18,19,22].

110 Considering the public health implications of healthcare decisions vis-à-vis their
111 pharmacoeconomic impact, numerous modifications to the tFMEA approaches have been
112 proposed. FMEA is considered a multi-attribute decision problem, hence Multicriteria Decision
113 Analysis (MCDA) such as Analytical Hierarchical Process (AHP) and Technique for Order of
114 Preference by Similarity to Ideal Solution (TOPSIS) have been independently and jointly
115 integrated to increase the reliability and robustness of failure mode prioritization [18]. The
116 concept of fuzzy logic was integrated into the MCDA tools to recapitulate FMEA team members'
117 intrapersonal and interpersonal divergence in logical reasoning [24].

118 Given the hitherto mentioned supply chain vulnerability, concerted efforts are vested by various
119 governmental and non-governmental organizations as well as interested researchers to gauge the
120 current status of ACTs. Medicines quality surveys are conducted as an external surveillance
121 feedback mechanism to regulators, manufacturers, patients, and all stakeholders in the
122 pharmaceutical supply chain [25]. The results of the survey may invoke a proactive risk
123 mitigation plans systems for the management of product non-conformances, complaints, recalls,
124 and continuous improvement plans [14]. The scientific literature on ACT quality assessment is
125 fairly rich [3,26–28]. However, only a few studies adopted a risk-based approach in ACT quality
126 risk analysis [4]. Moreover, the implementation of advanced FMEA analytics in quality
127 assessment of ACTs remains elusive amidst the growing need for proactive pharmaceutical risk
128 analysis in LIMCs, where both malaria and substandard antimalarials are endemic. This study
129 therefore aims at providing a systematic methodology for implementing a hybrid FMEA based
130 on fuzzy AHP integrated with fuzzy TOPSIS with a scope of strengthening the scientific quality
131 of critical quality risk analysis of ACTs in counterfeit endemic regions.

132 The methodology was presented as follows. First, we briefly introduce the concept of
133 fuzzy logic in the context of accounting for the expert’s vagueness in presenting their subjective
134 opinions based on FMEA risk factor evaluation scales. In the latter part, we implemented a
135 hybrid FMEA methodology based on fuzzy AHP and fuzzy TOPSIS in ACT failure mode
136 prioritization problem by cross-functional FMEA team members. The paper also aims to
137 communicate the computational utility of fuzzy logic, MCDA tools, and FMEA in a simplified
138 and straightforward form. Therefore, derivations of formulae and details of mathematical
139 theorems were out of the scope of the present work.

140 **Methodology for implementing hybrid fuzzy AHP and fuzzy TOPSIS in FMEA of** 141 **ACTs**

142 The urgent need for the fuzzy-based FMEA arose from an ongoing medicine quality
143 survey that aims at critically evaluating the current status of ACTs marketed in the various strata
144 of the pharmaceutical supply chains of three selected Northwestern states of Nigeria. The ethical
145 approval for the conduct of the study was granted by the College Research Ethics Committee of
146 the College of Health Sciences, Bayero University (Reference number: BUK/CHS-REC/121).
147 Samples of different brands of ACTs were collected from each stratum and multiple quality
148 attributes were analysed and documented using a modified Visual Tool for Quality Evaluation of
149 Medicines. Pharmacopoeial tests were conducted by the quality control team according to
150 USP41-NF 46. However, given the inherent limitations of the tFMEA highlighted above, a panel
151 of quality experts was constituted to develop the hybrid fuzzy FMEA methodology. The historic
152 quality control data of a blinded ACT sample was purposefully selected for this work

153 The cross-functional FMEA team comprises of five pharmaceutical quality experts with
154 diverse expertise in pharmaceutical analysis, pharmaceuticals and pharmaceutical technology,
155 pharmaceutical engineering, pharmacology, and therapeutics. Following brainstorming the
156 FMEA team members identified 15 failure modes. The team members recognized the limitations
157 of the tFMEA and opted for a hybrid FMEA based on fuzzy AHP and fuzzy TOPSIS algorithms
158 adopting the step-by-step procedure described in the subsequent sections.

159 **Formulation of the overall goal of the fuzzy FMEA model**

160 From the analytical hierarchical structure (Fig 3), the overall goal of the FMEA was to
161 prioritize the different failure modes of the ACT sample (Level 1). Level 2 represents the risk-
162 defining variables (criteria), also called the risk factors (O, S, and D). Level 3 represents the
163 various alternatives (failure modes in this case). In the fuzzy FMEA model, the scoring for the

164 relative importance of the risk factors was independently provided by each FMEA team member
165 by considering the crisp scale/linguistic terms of judgement provided in Table 1. Similarly, the
166 expert decision on each failure mode was independently provided by each FMEA team member
167 using Table 2-4. To aid in the visualization and comprehension of the tables, the triangular
168 membership functions (Fig 4-6) of the fuzzy numbers were created using Fuzzy Logic Designer
169 in MATLAB (Version 9.13.0, R2022).

170 **Fuzzy analytical hierarchy process**

171 In this method, we determined the weights of the risk factors using the extent analysis
172 method [29,30]. The FMEA team members' expert opinions of the three risk factors were
173 provided using the linguistic ratings in Table 1 [18]. Each of the experts utilized his scientific
174 judgment to value the risk factors. For convenience, we considered the crisp numeric values
175 equivalent to the linguistic ratings. Also, to avoid ambiguity and inconsistency of decisions, a
176 simple questionnaire was adopted from the literature (Supplementary file).

177 Let \tilde{C} be an n -ordered positive reciprocal matrix whose elements satisfy the condition
178 [31]:

$$179 \quad \tilde{c}_{ij} = \frac{1}{\tilde{c}_{ji}} \forall i, j \text{ and } \tilde{c}_{ij} > 0 \quad (3)$$

180 Then, the pairwise comparison matrix of the risk factors decision takes the form:

$$181 \quad \tilde{C} = [\tilde{c}_{ij}] = \begin{bmatrix} 1 & c_{12} & \cdots & c_{1n} \\ c_{21} & 1 & \cdots & c_{2n} \\ \vdots & \vdots & \ddots & \vdots \\ c_{n1} & c_{n2} & \cdots & 1 \end{bmatrix} \quad (4)$$

182 Also, Equation 5 describes a pairwise relation on the relative importance between two
183 risk factors. The detail of the scale of relative importance was given in Table 1 [18].

$$c_{ij} = \begin{cases} 1 & i = j \text{ risk factor} \\ c_{ij} & i \text{ risk factor} > j \text{ risk factor} \\ \frac{1}{c_{ji}} & i \text{ risk factor} < j \text{ risk factor} \end{cases} \quad (5)$$

185 Consistency analysis

186 To ensure that each expert opinion concerning risk factor weighting was consistent,
187 Saaty's consistency ratio (CR) was utilized (Equation 6).

$$188 \quad CR = \text{Consistency index}/\text{Random index} = (\lambda_{\max} - n/n - 1)/\text{Random index} \quad (6)$$

189 where λ_{\max} is the principal eigenvalue of \tilde{C} . Because the matrix was a 3x3, a random
190 index value of 0.58 calculated by Saaty was used. The acceptable consistent pairwise matrix was
191 considered for $CR \leq 0.1$ [31]. Inconsistent answers were sent back to the decision makers for
192 adjustment.

193 Fuzzification

194 After obtaining a consistent pairwise comparison matrix, the crips numeric decision of
195 the experts were converted into the corresponding fuzzy numbers.

196 Let A be a crips numeric value, and \tilde{A} be the corresponding fuzzy set whose elements are
197 (l, m, μ) which represents the vagueness of the expert decision. The optimum certainty of the
198 expert is represented by m , while the associated lower and upper deviations were respectively
199 denoted by l and μ [18]. The aggregated fuzzified pairwise comparison matrix was computed as:

$$200 \quad \tilde{A} = \tilde{c}_{ij} = (l_{ij}, m_{ij}, \mu_{ij}) \quad (7)$$

$$201 \quad l_{ij} = \min_k \{l_{ij}^k\}, m_{ij} = \frac{1}{5} \sum_{k=1}^5 m_{ij}^k, \mu_{ij} = \max_k \{\mu_{ij}^k\} \quad (8)$$

202 The general arithmetic operations with two positive triangular fuzzy numbers, \tilde{F}_1 and \tilde{F}_2 ,
203 are shown in Table 5 [18,19]. These general operations were used throughout the calculations.

204 Computation of fuzzy synthetic extent

205 The fuzzy synthetic extent (F_i) with respect to each risk variable was then calculated as in
 206 Equation 9 [18,29].

$$207 \quad F_i = \sum_{j=1}^n \tilde{c}_{ij} \otimes \left[\sum_{i=1}^n \sum_{j=1}^n \tilde{c}_{ij} \right]^{-1} \quad (9)$$

208 Secondly, the degree of superiority of the fuzzy synthetic extents was calculated
 209 according to Equation 10 [29,30]. Given that there were three risk factors, six degrees of
 210 superiorities were compared: $V(F_1 \geq F_2)$, $V(F_1 \geq F_3)$, $V(F_2 \geq F_1)$, $V(F_2 \geq F_3)$, $V(F_3 \geq F_1)$,
 211 $V(F_3 \geq F_2)$.

212 Generally, the degree of possibility that $F_1 \geq F_2$ was given by Equation 10 [18].

$$213 \quad V(F_1 \geq F_2) = \begin{cases} 1, & \text{if } m_1 \geq m_2 \\ 0, & \text{if } l_2 \geq \mu_1 \\ \frac{l_2 - \mu_1}{(m_1 - \mu_1) - (m_2 - l_2)}, & \text{otherwise} \end{cases} \quad (10)$$

214 Hence, the degree of possibility of a given convex fuzzy number to be superior than k
 215 convex fuzzy numbers was calculated using Equation 11. Accordingly, the weight vector and it's
 216 normalized for were determined according to Equation 12 and 13, respectively [29,30].

$$217 \quad V(F \geq F_1, \dots, F_k) = \min V(F \geq F_i), i = 1, 2, \dots, k \quad (11)$$

$$218 \quad d'(A_i) = \min V(F_i \geq F_k), i, k = 1, 2, \dots, n; k \neq i \quad (12)$$

$$219 \quad W' = ((d'(A_1), d'(A_2), d'(A_3))^T \quad (13)$$

220 ***Fuzzy TOPSIS expert assessment of failure modes***

221 On the basis of the historic quality analysis data of the ACT sample, the cross-functional
 222 team members provided subjective assessment of each failure mode. Compliance of
 223 pharmacopoeial specifications were considered as benchmark for assessment of optimum
 224 compliance to quality standards. The risk posed to the ACT quality was subjectively evaluated
 225 based on deviation from pharmacopoeial tolerance limits of the investigated quality attributes.

226 This was supplemented by regional regulatory requirements to critical quality requirements
 227 where applicable. Again, each team member was instructed to use linguistic terms, which in our
 228 case were equivalent to the crisps numeric values for ranking the occurrence, severity, and
 229 detection based on Table 2, 3, and 4, respectively.

230 The crisp ratings were converted to corresponding fuzzy numbers and the aggregated
 231 subjective group opinion matrix computed using Equation 14 [22].

$$232 \quad E = [e_{ij}]_{mn} \quad (14)$$

233 *Normalization of the combined/aggregated fuzzy decision matrix*

234 Sets of beneficial (ξ) and cost (ζ) risk factors were assigned based on the synthesized risk
 235 variable weights. We hypothetically considered the low-weighted risk factors as the ξ , while the
 236 high-weighted risk factor as the ζ . Normalization of the aggregated FMEA opinion proceed
 237 according to Equation 15 and 17, respectively [18,32–35].

$$238 \quad \tilde{e}_{ij} = \left(\frac{l_{ij}}{\mu_j^*}, \frac{m_{ij}}{\mu_j^*}, \frac{\mu_{ij}}{\mu_j^*} \right), j \in \xi \quad (15)$$

239 where,

$$240 \quad \mu_j^* = \text{Max}_i\{\mu_{ij}\}, j \in \xi \quad (16)$$

$$241 \quad \tilde{e}_{ij} = \left(\frac{l_j^-}{\mu_{ij}}, \frac{l_j^-}{m_{ij}}, \frac{l_j^-}{l_{ij}} \right), j \in \zeta \quad (17)$$

242 where,

$$243 \quad l_j^- = \text{Min}_i\{l_{ij}\}, j \in \zeta \quad (18)$$

244 *Computation of weighted normalized fuzzy decision matrix*

245 To obtain the normalized fuzzy decision matrix, the weight vectors were multiplied with
 246 fuzzy decision matrix.

$$247 \quad \tilde{z}_{ij} = (\tilde{e}_{ij})(w_j) \quad (19)$$

248 *Determination of Fuzzy Positive Ideal Solution (F^*) and Fuzzy Negative Ideal Solution*
 249 *(F^-)*

250 The fuzzy positive ideal solution and fuzzy negative ideal solution were identified using
 251 Equation 20 and 21, respectively [32,35].

$$252 \quad F^* = (\tilde{f}_1^*, \tilde{f}_2^*, \dots, \tilde{f}_n^*), \text{ where } f_j^* = \max_i\{v_{ij3}\} \quad (20)$$

$$253 \quad F^- = (\tilde{f}_1^-, \tilde{f}_2^-, \dots, \tilde{f}_n^-), \text{ where } \tilde{f}_j^- = \min_i\{v_{ij1}\} \quad (21)$$

$$254 \quad i = 1, 2, \dots, m \text{ and } j = 1, 2, \dots, n$$

255 *Computation of the distance of each FMI from F^* and F^-*

256 In general terms, the distance between two triangular fuzzy numbers $\tilde{\alpha}$ and $\tilde{\beta}$ can be
 257 calculated using Equation 22 [35]. Accordingly, the distances of each failure mode from fuzzy
 258 positive ideal solution and fuzzy negative ideal solution were calculated using Equation 23 and
 259 24, respectively [18,33,35].

$$260 \quad d(\tilde{\alpha}, \tilde{\beta}) = \left(\frac{[(\alpha_1 - \beta_1)^2 + (\alpha_2 - \beta_2)^2 + (\alpha_3 - \beta_3)^2]}{3} \right)^{\frac{1}{2}} \quad (22)$$

$$261 \quad \delta_i^* = \sum_{j=1}^n d(\tilde{f}_{ij}, \tilde{f}_j^*) \quad (23)$$

$$262 \quad \delta_i^- = \sum_{j=1}^n d(\tilde{f}_{ij}, \tilde{f}_j^-) \quad (24)$$

263 *Closeness coefficient*

264 On the basis of Equation 24, failure mode a failure mode was deemed closer to F^* and
 265 distant from F^- as the closeness coefficient tends to unity [35].

$$266 \quad cc_i = \frac{\delta_i^-}{\delta_i^* + \delta_i^-} \quad (25)$$

267

268 **Results and discussion**

269 *Fuzzy AHP for Group analysis of the relative importance of the risk variables*

270 In FMEA critical evaluation of quality risk of pharmaceutical products is a collective
271 responsibility of the cross-functional quality experts whose opinions on the comparative weights
272 of the risk-determining variables were highly subjective. The analytical hierarchy process (AHP)
273 is a powerful technique for establishing the degree of comparative superiority between criteria in
274 practical MCDA [29,30]. The risk defining variables in the tFMEA are not equally important,
275 and treating them as such in risk priority calculation would result in non-reliable results. With the
276 help of AHP the hierarchical connections of the risk variables can be analysed and their relative
277 weights defined. However, AHP does not factor in the vagueness of the cross functional team
278 members in making pairwise comparison. By integrating fuzzy logic concept into AHP, this
279 problem could be adequately resolved [18,24,29].

280 In this study, the team members utilized their professional and scientific judgements to
281 linguistically rank the three risk variables in a pairwise form. To resolve the uncertainties or
282 impreciseness associated with subjective expert assessment of the risk factors, each linguistic
283 term (denoted by the crisp numeric value) was converted in to the corresponding triangular fuzzy
284 number. In this form, the subjectivities of the experts concerning their perception of the risk
285 factors is numerically presented and conceptually appreciated. At this point, the uncertainty and
286 impreciseness were apparent as all the pairwise comparison matrices were non-identical (Table
287 6). This was more evident in the individual and aggregated fuzzified pairwise comparison matrix
288 (Table 7-8). However, throughout each expert decision matrix, transitivity rule was observed to

289 ensure that pairwise relations of the risk variables were not contradictory. Inconsistent pairwise
290 comparison results in errors in the computation of the aggregated hierarchical weights with
291 consequences on the reliability of the final failure mode prioritization. Therefore, to ensure
292 consistent judgement, each pairwise comparison matrix was analysed using Saaty's CR [31].
293 Initially, there were two situations with inconsistent judgement ($CR \gg 0.1$), but the questionnaire
294 was sent back to the concerned TM to rectify the situation. Finally, in all expert opinions, a value
295 of $CR < 0.1$ was obtained before proceeding to aggregate the individual fuzzified matrices into
296 fuzzy group decision matrix. The aggregated fuzzified expert opinion formed the group opinion
297 of the risk factor weights for subsequent extent analysis.

298 In the latter part of the fuzzy AHP extent analysis, a pairwise analysis of the degree to
299 which risk factor i outweighs risk factor j was computed. Thus, based on Equation 9 the
300 computed fuzzy synthetic were as follows:

$$F_1 = (1.24, 8.49, 17) \times \left(\frac{1}{49} \cdot \frac{1}{18.89}, \frac{1}{3.85} \right) = (0.02, 0.43, 4.45)$$

$$F_2 = (1.24, 3.86, 13) \times \left(\frac{1}{49} \cdot \frac{1}{18.89}, \frac{1}{3.85} \right) = (0.02, 0.2, 3.4)$$

$$F_3 = (1.38, 6.55, 19) \times \left(\frac{1}{49} \cdot \frac{1}{18.89}, \frac{1}{3.85} \right) = (0.03, 0.33, 4.97)$$

301 Similarly, Equation 10 provided a conditional relation for determining the degrees of
302 possibilities for fuzzy synthetic extent i to be greater than j as: $V(F1 \geq F2) = 1$, $V(F1 \geq F3) =$
303 1 , $V(F2 \geq F1) = 0.6452$, $V(F2 \geq F3) = 0.7463$, $V(F3 \geq F1) = 0.6582$, $V(F3 \geq F2) = 1$.
304 Hence, after comparisons of the degree of possibilities it was found that $V(F1 \geq F2, F3) = 1$,
305 $V(F2 \geq F1, F3) = 0.6452$, $V(F3 \geq F1, F2) = 0.6582$. Finally, the normalized weight vectors
306 were $W^O = 0.43$, $W^S = 0.28$, and $W^D = 0.29$ for O, S, and D, respectively.

307 The normalized risk variable weights indicated that the risk variable O was more
308 important than S and D. On this basis, O was hypothetically assigned as non-beneficial criteria
309 and their minimum value was desired in the risk computation. Although S was slightly greater
310 than D, both risk factors were designated as beneficial criteria, and hence their maximum values
311 were desired.

312 *Fuzzy TOPSIS ranking of the failure modes*

313 There were 15 failure modes each of which received an O, S, and D risk scores by each
314 cross-functional team member based on the scales provided in Table 2, 3, and 3, respectively.
315 The crisp numeric value for each risk score indicates the team member's expert judgement on
316 that factor. It was also evident that, the inherent intrapersonal subjectivities were not captured by
317 the crisp values, in contrast to the fuzzified risk score based on the triangular fuzzy numbers. The
318 aggregated group decision of all risk defining variable for all failure modes was presented in
319 Table 8.

320 Unlike the fuzzy AHP analysis, the TOPSIS had the advantage of circumventing the need
321 for pairwise comparison, which would otherwise make the individual and aggregated decisions
322 matrices cumbersome. Also, there were no priority requirement for assuring transitivity rule and
323 consistency ratios as well as the need for computation of fairly large number of fuzzy synthetic
324 extents and their degree of relations.

325 The greatest advantage of TOPSIS utilized in this study was in rankings the large
326 numbers of failure modes. Accordingly, the fuzzy TOPSIS was geared towards capturing the
327 vagueness of the team members opinions. To achieve this, we explored the fundamental
328 principles of TOPSIS where alternatives were ranked on the based on the Euclidean distances
329 from hypothetical ideal and non-ideal solutions.

330 In FMEA, the higher the risk factor score, the more the risk priority number [19]. Hence,
331 in our study we conditioned the risk variable with highest group weight of importance as the
332 non-beneficial criteria. Conversely, the low weight bearing factors were regarded as beneficial
333 criteria. Following determination of the closeness coefficient, the ranking of the failure modes
334 in descending order of risk priorities were FM9> FM12> FM13> FM10> FM11> FM2>
335 FM4> FM6> FM3> FM1> FM5> FM7>FM8> FM15> FM14 (Table 10).

336 The closeness coefficient provided the basis of ranking of all the failure modes (Table
337 10). FM9 recorded the lowest CCI signifying its closest proximity to the negative ideal solution,
338 and thus the highest risk of all the analysed failure modes. FM9 relates to failure in the ACT
339 tablets to disintegrate based on USP 41-NF36 in vitro disintegration monograph. Although the
340 historic quality control data indicated that the ACT tablets were immediate-release, some of the
341 dosage units failed to disintegrate even after 1 hour signifying critical quality failure.

342 Similarly, FM12 and FM13 recorded the second and third closest distances to the
343 negative ideal solution. These failure modes relate to the non-conformances in percentage label
344 claims of artemether and lumefantrine, respectively. The pharmacopoeia specified the acceptable
345 label claims to be not less than 90% and not more than 110% of either of the active agents.
346 However, the historic data indicate that both artemether and lumefantrine in the ACT tablets fell
347 below the acceptable official threshold.

348 Concerning proximity to fuzzy positive ideal solution, FM14 recorded the highest
349 closeness coefficient. The historic data indicated that the ACT tablets were mechanically strong
350 as they were characterized by friability values within the pharmacopoeial acceptable limits.
351 FM15 and FM8 were the second and third closest to the positive ideal solution, respectively.

352 Although, this novel approach is an enhanced adaptation of the tFMEA, it is not without
353 inherent limitations. There are several variants of AHP for according criteria weights. This may
354 likely affect the order of risk factor importance priorities, which may affect the categorization of
355 the variables as beneficial and non-beneficial risk variables. We therefore recommend further
356 studies to corroborate the current findings and also explore other variants of fuzzy multicriteria
357 decision analysis in quality risk analysis of ACTs.

358 **Conclusion**

359 FMEA is a crucial proactive quality risk analysis tool in lifecycle management of
360 Artemisinin-based Combination Therapies (ACTs) to assure quality and safety status. The
361 tradition FMEA methodology has critical limitations that compromises the reliability of risk
362 prioritization. The advanced hybrid fuzzy FMEA methodologies presented in this paper is
363 consistent with the current regulatory paradigm shifts from “empirical thinking” to “scientific
364 thinking”, as contextualized in the ICH Q9 (Quality Risk Management) and Q10
365 (Pharmaceutical Quality Systems) guidelines.

366 The novel fuzzy FMEA model captures the diverse subjectivities of the cross functional
367 team by fuzzification of the linguistic and crips values to fuzzy numbers and membership
368 functions. Secondly, the analytical hierarchy process provided a reliable computational way of
369 weighting the risk-determining variables. The fuzzy TOPSIS provides an easily configurable
370 ranking of the alternatives (failure modes) on the basis of their Euclidean distances from positive
371 and negative solutions.

372 This study targets to strengthen the capacity and scientific quality of quality risk analysis
373 of ACTs by all stakeholders involved risk mitigation and containment strategies particularly in
374 LIMCs where both malaria and substandard antimalarials are endemic.

375 **Data availability**

376 All data produced are available online via the link:
377 <https://data.mendeley.com/preview/hg7z83brcv?a=d8f53913-d5a9-4a49-8964->.

378 **Acknowledgement**

379 We sincerely appreciate the funding received through the National Research Fund of the Tertiary
380 Education Trust Fund Grant Number TETF/DR&D/CE/NRF/CC/20/VOL 1.

381 **References**

- 382 [1] Malaria [Internet]. [cited 2023 Nov 19]. Available from: [https://www.who.int/news-](https://www.who.int/news-room/fact-sheets/detail/malaria)
383 [room/fact-sheets/detail/malaria](https://www.who.int/news-room/fact-sheets/detail/malaria).
- 384 [2] Malaria: Artemisinin partial resistance [Internet]. [cited 2024 Jan 26]. Available from:
385 <https://www.who.int/news-room/questions-and-answers/item/artemisinin-resistance>.
- 386 [3] Ocan M, Nakalembe L, Otike C, et al. Pharmacopeial quality of artemether–lumefantrine
387 anti-malarial agents in Uganda. *Malar J* [Internet]. 2023 [cited 2023 Nov 21];22:1–11.
388 Available from: [https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04600-8)
389 [04600-8](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04600-8).
- 390 [4] Belew S, Suleman S, Mohammed T, et al. Quality of fixed dose artemether/lumefantrine
391 products in Jimma Zone, Ethiopia. *Malar J* [Internet]. 2019 [cited 2023 Nov 21];18:1–11.
392 Available from: [https://malariajournal.biomedcentral.com/articles/10.1186/s12936-019-](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-019-2872-1)
393 [2872-1](https://malariajournal.biomedcentral.com/articles/10.1186/s12936-019-2872-1).
- 394 [5] Lee S-H, Kim J-K, Jee J-P, et al. Quality by Design (QbD) application for the
395 pharmaceutical development process. *Journal of Pharmaceutical Investigation* 2022
396 [Internet]. 2022 [cited 2022 Sep 20];1–34. Available from:
397 <https://link.springer.com/article/10.1007/s40005-022-00575-x>.

- 398 [6] Hauk C, Hagen N, Heide L. Identification of Substandard and Falsified Medicines:
399 Influence of Different Tolerance Limits and Use of Authenticity Inquiries. *Am J Trop*
400 *Med Hyg* [Internet]. 2021 [cited 2024 Jan 26];104:1936. Available from:
401 [/pmc/articles/PMC8103440/](https://pubmed.ncbi.nlm.nih.gov/38103440/).
- 402 [7] Karunamoorthi K. The counterfeit anti-malarial is a crime against humanity: A systematic
403 review of the scientific evidence. *Malar J* [Internet]. 2014 [cited 2023 Nov 20];13:1–13.
404 Available from: <https://link.springer.com/articles/10.1186/1475-2875-13-209>.
- 405 [8] Newton PN, Taberner P, Dwivedi P, et al. Falsified medicines in Africa: All talk, no
406 action. *Lancet Glob Health* [Internet]. 2014 [cited 2023 Nov 21];2:e509–e510. Available
407 from: <http://www.thelancet.com/article/S2214109X14702797/fulltext>.
- 408 [9] Newton PN, McGready R, Fernandez F, et al. Manslaughter by fake artesunate in Asia-
409 will Africa be next? *PLoS Med*. 2006;3:e197.
- 410 [10] ICH Official web site: ICH [Internet]. [cited 2023 Nov 21]. Available from:
411 <https://www.ich.org/page/quality-guidelines>.
- 412 [11] Bassat Q, Tanner M, Guerin PJ, et al. Combating poor-quality anti-malarial medicines: A
413 call to action. *Malar J*. 2016;15.
- 414 [12] Project D. Guidelines for Managing the Malaria Supply Chain: A Companion to the
415 Logistics Handbook. 2011;
- 416 [13] Liu H-C. FMEA for Proactive Healthcare Risk Analysis: A Systematic Literature Review.
417 Improved FMEA Methods for Proactive Healthcare Risk Analysis [Internet]. 2019 [cited
418 2024 Jan 26];15–45. Available from: [https://link.springer.com/chapter/10.1007/978-981-](https://link.springer.com/chapter/10.1007/978-981-13-6366-5_2)
419 [13-6366-5_2](https://link.springer.com/chapter/10.1007/978-981-13-6366-5_2).

- 420 [14] ICH Official web site: ICH [Internet]. [cited 2024 Jan 25]. Available from:
421 <https://ich.org/page/briefing-pack>.
- 422 [15] Anjalee JAL, Rutter V, Samaranayake NR. Application of Failure Mode and Effect
423 Analysis (FMEA) to improve medication safety: A systematic review. *Postgrad Med J*.
424 2021;97:168–174.
- 425 [16] Liu HC, Zhang LJ, Ping YJ, et al. Failure mode and effects analysis for proactive
426 healthcare risk evaluation: A systematic literature review. *J Eval Clin Pract* [Internet].
427 2020 [cited 2024 Jan 26];26:1320–1337. Available from:
428 <https://pubmed.ncbi.nlm.nih.gov/31849153/>.
- 429 [17] Tsai SB, Zhou J, Gao Y, et al. Combining FMEA with DEMATEL models to solve
430 production process problems. *PLoS One* [Internet]. 2017 [cited 2024 Jan
431 14];12:e0183634. Available from:
432 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183634>.
- 433 [18] Kutlu AC, Ekmekçioğlu M. Fuzzy failure modes and effects analysis by using fuzzy
434 TOPSIS-based fuzzy AHP. *Expert Syst Appl*. 2012;39:61–67.
- 435 [19] Wang YM, Chin KS, Poon GKK, et al. Risk evaluation in failure mode and effects
436 analysis using fuzzy weighted geometric mean. *Expert Syst Appl*. 2009;36:1195–1207.
- 437 [20] Kuhn KM, Budescu D V. The Relative Importance of Probabilities, Outcomes, and
438 Vagueness in Hazard Risk Decisions. *Organ Behav Hum Decis Process*. 1996;68:301–
439 317.
- 440 [21] Takemura K. Vagueness in Human Judgment and Decision Making. 2000 [cited 2024 Jan
441 26];249–281. Available from: [https://link.springer.com/chapter/10.1007/978-4-431-](https://link.springer.com/chapter/10.1007/978-4-431-67907-3_10)
442 [67907-3_10](https://link.springer.com/chapter/10.1007/978-4-431-67907-3_10).

- 443 [22] Liu HC, Liu L, Bian QH, et al. Failure mode and effects analysis using fuzzy evidential
444 reasoning approach and grey theory. *Expert Syst Appl*. 2011;38:4403–4415.
- 445 [23] Qin J, Xi Y, Pedrycz W. Failure mode and effects analysis (FMEA) for risk assessment
446 based on interval type-2 fuzzy evidential reasoning method. *Appl Soft Comput*.
447 2020;89:106134.
- 448 [24] Boral S, Howard I, Chaturvedi SK, et al. An integrated approach for fuzzy failure modes
449 and effects analysis using fuzzy AHP and fuzzy MAIRCA. *Eng Fail Anal*.
450 2020;108:104195.
- 451 [25] Newton PN, Lee SJ, Goodman C, et al. Guidelines for Field Surveys of the Quality of
452 Medicines: A Proposal. *PLoS Med* [Internet]. 2009 [cited 2023 Nov 21];6:e1000052.
453 Available from:
454 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000052>.
- 455 [26] Newton PN, Green MD, Mildenhall DC, et al. Poor quality vital anti-malarials in Africa -
456 An urgent neglected public health priority. *Malar J*. 2011;10.
- 457 [27] Kaur H, Allan EL, Mamadu I, et al. Quality of Artemisinin-Based Combination
458 Formulations for Malaria Treatment: Prevalence and Risk Factors for Poor Quality
459 Medicines in Public Facilities and Private Sector Drug Outlets in Enugu, Nigeria. *PLoS*
460 *One* [Internet]. 2015 [cited 2023 Nov 21];10:e0125577. Available from:
461 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0125577>.
- 462 [28] Almuzaini T, Choonara I, Sammons H. Substandard and counterfeit medicines: a
463 systematic review of the literature. *BMJ Open* [Internet]. 2013 [cited 2023 Nov
464 21];3:e002923. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23955188>.

- 465 [29] Chang DY. Applications of the extent analysis method on fuzzy AHP. *Eur J Oper Res.*
466 1996;95:649–655.
- 467 [30] Liu Y, Eckert CM, Earl C. A review of fuzzy AHP methods for decision-making with
468 subjective judgements. *Expert Syst Appl.* 2020;161:113738.
- 469 [31] Kumar A;□;, Ram M;., Klochkov Y;., et al. Consistency Indices in Analytic Hierarchy
470 Process: A Review. *Mathematics* 2022, Vol 10, Page 1206 [Internet]. 2022 [cited 2024
471 Jan 6];10:1206. Available from: <https://www.mdpi.com/2227-7390/10/8/1206/htm>.
- 472 [32] Erdem G, Ulutagay G, Paldrak M. Supplier Selection with Fuzzy TOPSIS- A Case Study
473 on a Pharmacy in Izmir. 2023 [cited 2023 Nov 20];138–148. Available from:
474 https://link.springer.com/chapter/10.1007/978-3-031-25847-3_14.
- 475 [33] Palczewski K, Sałabun W. The fuzzy TOPSIS applications in the last decade. *Procedia*
476 *Comput Sci.* 2019;159:2294–2303.
- 477 [34] Mangeli M, Shahraki A, Saljooghi FH. Improvement of risk assessment in the FMEA
478 using nonlinear model, revised fuzzy TOPSIS, and support vector machine. *Int J Ind*
479 *Ergon.* 2019;69:209–216.
- 480 [35] Chen CT. Extensions of the TOPSIS for group decision-making under fuzzy environment.
481 *Fuzzy Sets Syst.* 2000;114:1–9.
- 482
- 483

484 Table 1: Linguistic, crips, and fuzzy ratings for risk factor weighting.

Linguistic term	Crips values	Fuzzy numbers
Equal preference (EP)	1	(1, 1, 1)
Moderate preference (MP)	3	(2, 3, 4)
Strong preference (SP)	5	(4, 5, 6)
Very strong preference (VSP)	7	(6, 7, 8)
Extremely strong preference (EP)	9	(9, 9, 9)

485

486 Table 2: Linguistic, crips, and fuzzy ratings for occurrence [19].

Linguistic rating	Symbol	Description of probability of Occurrence	Crips value	Fuzzy numbers
Very high	VH	Inevitable	10	9,10,10
High	H	Repeated	7	7, 8, 9
Moderate	M	Occasional	5	4, 6, 7
Low	L	Few	3	2,3,4
Remote	R	Unlikely	1	1, 1, 2

487

488

489

490

491

492

493 Table 3: Linguistic, crips, and Fuzzy ratings for Severity.[19]

Linguistic term	Symbol	Description of severity	Crips value	Fuzzy numbers
None	N	No effect on ACT quality	1	1,1,2
Very minor	VMN	Very minor effect on ACT quality	2	1,2,3
Minor	MN	Minor effect on product quality	3	2,3,4
Very low	VL	Very low effect on ACT quality	4	3,4,5
Low	L	Low on ACT quality	5	4,5,6
Moderate	M	Moderate impact to ACT quality	6	5,6,7
High	H	High impact to ACT quality	7	6,7,8
Very high	VH	Very high impact on ACT quality	8	7,8,9
Hazardous with warning	HWW	Hazardous effect on the ACT (with warning)	9	8,9,10
Hazardous without warning	HWOW	Hazardous effect on the ACT (without warning)	10	9,10,10

494

495

496

497 Table 4: Linguistic, crips, and Fuzzy ratings for Detection.[19]

Linguistic rating	Symbol	Description of likelihood of detection	Crips value	Fuzzy numbers
Absolute uncertainty	AU	Design control will not and/or cannot detect potential failure.	10	9, 10, 10
Very remote	VR	The chance that the design control will detect potential failure is very remote	9	8, 9, 10
Remote	R	The chance that the design control will detect potential failure is remote	8	7, 8, 9
Very low	VL	The chance that the design control will detect potential failure is very low	7	6, 7, 8
Low	L	The chance that the design control will detect potential failure is low	6	5, 6, 7
Moderate	M	The chance that the design control will detect potential failure is moderate	5	4, 5, 6
Moderately high	NH	The chance that the design control will detect potential failure I moderately high	4	3, 4, 5
High	H	The chance that the design control will detect potential failure is high	3	2, 3, 4
Very high	VH	The chance that the design control will detect potential failure is very high	2	1, 2, 3
Certain	C	The chance that the design control will detect potential failure is certain	1	1, 1, 2

Table 5: General arithmetic operations for calculations with positive triangular fuzzy numbers.

Operation	Applied fuzzy operation
Addition	$\tilde{F}_1 \oplus \tilde{F}_2 = (l_1, m_1, \mu_1) \oplus (l_2, m_2, \mu_2) = (l_1 + l_2, m_1 + m_2, \mu_1 + \mu_2)$
Multiplication	$\tilde{F}_1 \otimes \tilde{F}_2 = (l_1, m_1, \mu_1) \otimes (l_2, m_2, \mu_2) = (l_1 \times l_2, m_1 \times m_2, \mu_1 \times \mu_2)$
Division	$\tilde{F}_1 \div \tilde{F}_2 \approx \left(\frac{l_1}{\mu_2}, \frac{m_1}{m_2}, \frac{\mu_1}{l_2} \right)$
Subtraction	$\tilde{F}_1 - \tilde{F}_2 = (l_1 - l_2, m_1 - m_2, \mu_1 - \mu_2)$

Table 6: Pairwise comparison matrix of risk factors (crisps values) of each cross functional team member.

FMEA Team members (TM)	Crisps pairwise comparison matrix				Consistency ratio
TM 1		O	S	D	
	O	1	5	7	
	S	1/5	1	3	
	D	1/7	1/3	1	0.074
TM 2		O	S	D	
	O	1	1/7	1/9	
	S	7	1	1/2	0.05
	D	9	2	1	
TM 3		O	S	D	
	O	1	6	4	0.08
	S	1/6	1	2	
	D	1/4	1/2	1	
TM 4		O	S	D	0.08
	O	1	7	2	
	S	1/7	1	1	
	D	1/2	1	1	0.08
TM 5		O	S	D	
	O	1	6	1/5	
	S	1/6	1	1/9	0.08
	D	5	9	1	

O: Occurrence, S: Severity, D: Detection

Table 7: Fuzzified pairwise comparison matrix of risk factors by individual cross functional team members.

FMEA Team members (TM)	Fuzzified pairwise comparison matrix			
TM 1		O	S	D
	O	(1, 1, 1)	(4, 5, 6)	(6, 7, 8)
	S	(0.17, 0.2, 0.25)	(1, 1, 1)	(2, 3, 4)
	D	(0.13, 0.14, 0.17)	(0.25, 0.33, 0.5)	(1, 1, 1)
TM 2		O	S	D
	O	(1, 1, 1)	(0.13, 0.14, 0.17)	(0.11, 0.11, 0.11)
	S	(6, 7, 8)	(1, 1, 1)	(0.33, 0.5, 1)
	D	(9, 9, 9)	(1, 2, 3)	(1, 1, 1)
TM 3		O	S	D
	O	(1, 1, 1)	(5, 6, 7)	(3, 4, 5)
	S	(0.14, 0.17, 0.2)	(1, 1, 1)	(1, 2, 3)
	D	(0.2, 0.25, 0.33)	(0.33, 0.5, 1)	(1, 1, 1)
TM 4		O	S	D
	O	(1, 1, 1)	(6, 7, 8)	(1, 2, 3)
	S	(0.13, 0.14, 0.17)	(1, 1, 1)	(1, 1, 1)
	D	(0.33, 0.5, 1)	(1, 1, 1)	(1, 1, 1)
TM 5		O	S	D
	O	(1, 1, 1)	(5, 6, 7)	(0.17, 0.2, 0.25)

	S	(0.14, 0.17, 0.2)	(1, 1, 1)	(0.11, 0.11, 0.11)
	D	(4, 5, 6)	(9, 9, 9)	(1, 1, 1)

O: Occurrence, S: Severity, D: Detection

Table 8: Aggregated Fuzzified pair-wise comparison matrix of all cross functional team members.

Risk factors	O	S	D	Normalized weight vector
O	(1, 1, 1)	(0.125, 4.83, 8)	(0.11, 2.66, 8)	0.43
S	(0.13, 1.54, 8)	(1, 1, 1)	(0.11, 1.32, 4)	0.28
D	(0.13, 2.97, 9)	(0.25, 2.57, 9)	(1, 1, 1)	0.29

Table 9: Aggregated fuzzified ratings of the failure modes.

Failure mode code	Occurrence	Severity	Detection
FM1	(1, 1.8, 4)	(1, 2.8, 9)	(1, 3.2, 10)
FM2	(1, 4.5, 10)	(1, 4.5, 10)	(1, 4.25, 9)
FM3	(1, 3, 7)	(1, 3.6, 10)	(1, 2.8, 7)
FM4	(2, 5.4, 9)	(2, 5.4, 10)	(1, 4.4, 7)
FM5	(2, 5.2, 7)	(1, 5, 9)	(1, 3, 6)
FM6	(1, 3.6, 7)	(1, 4, 8)	(1, 3.6, 10)
FM7	(1, 4.6, 10)	(1, 4.2, 10)	(1, 2, 5)
FM8	(1, 4.2, 10)	(1, 4.4, 10)	(1, 1.8, 5)
FM9	(4, 8.2, 10)	(7, 9.2, 10)	(1, 4.6, 10)
FM10	(1, 3.2, 10)	(1, 3, 10)	(1, 4.8, 10)

FM11	(1, 3.2, 10)	(1, 3, 10)	(1, 4.6, 10)
FM12	(4, 8.6, 10)	(6, 8.8, 10)	(1, 5.2, 10)
FM13	(2, 6.2, 10)	(2, 6.6, 10)	(1, 5.4, 10)
FM14	(1, 3.6, 10)	(1, 4.2, 10)	(1, 1.6, 4)
FM15	(1, 3.8, 10)	(1, 4, 10)	(1, 1.6, 3)

Table 10: Closeness coefficient and final failure modes ranking.

Failure mode code	d+			δ^*	d-			δ^-	CCI	Risk priority ranking
	O	S	D		O	S	D			
FM1	0.2224 8	0.3712 8	0.4469 6	1.0407 2	0.7509 7	0.4170 9	0.5981 3	1.7661 8	0.6292 3	10
FM2	0.1901	0.4680 1	0.4484 6	1.1065 6	0.5462 9	0.5622	0.6072 1	1.7157	0.6079 2	6
FM3	0.1929 5	0.4387 5	0.2762 3	0.9079 3	0.5964 6	0.5072 3	0.4299 6	1.5336 5	0.6281 4	9
FM4	0.0294 3	0.5025 6	0.3760 2	0.9080 1	0.2725 2	0.6445 6	0.5340 6	1.4511 4	0.6151 1	7
FM5	0.0304	0.4428 4	0.2400 8	0.7133 2	0.2856 1	0.5577 3	0.3963 3	1.2396 7	0.6347 6	11
FM6	0.1908	0.3458 7	0.4630 8	0.9997 6	0.5721 7	0.4458 1	0.6174 5	1.6354 2	0.6206 1	8
FM7	0.1901	0.4565	0.1470	0.7937	0.5447	0.5428	0.2923	1.3800	0.6348	12


	5		5		8	4	9	1	6	
FM8	0.1900 2	0.4639 9	0.1424 4	0.7964 4	0.5515	0.5556 4	0.2823 9	1.3895 3	0.6356 6	13
FM9	0.0715 9	0.9303 7	0.5149	1.5168 7	0.1232 7	1.1544 2	0.6737 7	1.9514 5	0.5626 5	1
FM10	0.1915 9	0.4287 4	0.5269 4	1.1472 6	0.5811	0.4765 4	0.6862 3	1.7438 6	0.6031 8	4
FM11	0.1915 9	0.4287 4	0.5149	1.1352 3	0.5811	0.4765 4	0.6737 7	1.7314 1	0.6039 9	5
FM12	0.0726 4	0.8505 3	0.5523 9	1.4755 6	0.1200 4	1.0689	0.7121 8	1.9011 2	0.5630 2	2
FM13	0.0349 3	0.5785 7	0.5657 5	1.1792 4	0.2588 2	0.7352 8	0.7256 3	1.7197 3	0.5932 2	3
FM14	0.1904 6	0.4565	0.0953 2	0.7422 7	0.5662 6	0.5428 4	0.2249 5	1.3340 5	0.6425 1	15
FM15	0.1901 9	0.4497 7	0.0713 2	0.7112 7	0.5605 4	0.5304 8	0.1818 5	1.2728 7	0.6415 2	14

CCI: Closeness coefficient.

Table 11: Description of failure modes and the final ranking.

Failure mode	Failure mode description	Risk priority ranking
FM1	Failed mobile authentication service (MAS). There was no feedback when the code was sent for authentication via short message service.	10
FM2	Inappropriate primary packaging/Containers not properly sealed/.	6
FM3	Labelling issues. Legibility and indelibility of label information; Trade name misspelled/Inconsistent spelling of API/Conformity to registered drug. Leaflet explaining dosage, the drug content, the adverse effects, the drug actions, and how the drug should be taken absent in the product (Also not printed on the secondary pack). Smudge proof. Legibility and indelibility of the information.	9
FM4	Hologram/Logo not authentic (e.g does not change when viewed from different angle	7
FM5	Tablets not coated (Sugar coating, enteric coating absent)	11
FM6	List of excipients not provided.	8
FM7	The tablets/capsules not uniform in shape/size/Surface coatings/Texture/Scoring/Odour. Presence of breaks, cracks, splits, or pinholes; Tablets/capsules not free of embedded surface spots and foreign particle contamination	12
FM8	Presence of empty tablets/capsules in the package	13
FM9	Tablets not disintegrating.	1
FM10	Identification: absence of Artemether in the dosage form	4

FM11	Identification: absence of Lumefantrine in the dosage form	5
FM12	Percentage label claim_Artemether content outside the allowed range (90-110%). Not more than 110%, and not less than 90% of artemether	2
FM13	Percentage label claim_Lumefantrine content outside the allowed range (90-110%). Not more than 110%, and not less than 90% of Lumefantrine	3
FM14	Tablet friability	15
FM15	Tablets not uniform in weight	14




1

2 Figure 1: Triangular membership function. Here $l=3$, $m=5$, $\mu=7$.

3

4




5

6 Figure 2: Systematic methodology for a hybrid fuzzy analytical hierarchy process and fuzzy
 7 TOPSIS in failure mode effect analysis of fixed-dose artemether-lumefantrine tablets.
 8 VisToolsQEM: Visual Tool for Quality Evaluation of Medicines, FMEA: Failure Mode Effect
 9 Analysis, PQS: Pharmaceutical Quality Systems, QRM: Quality Risk Management, TOPSIS:

10 Technique for Order of Preference by Similarity to Ideal Solution. $F\delta^*$: Fuzzy positive ideal
11 solution, $F\delta^-$: Fuzzy negative ideal solution.

12



13

14 Figure 3: Analytical Hierarchy structure for failure mode prioritization. Level 1 is the goal of the
15 Analytical Hierarchy Process, which is to prioritize the failure modes of the Artemether-
16 Lumefantrine fixed-dose combination tablets. Level 2 represents the risk factors for probability
17 of occurrence (O), Severity of failure (S), and likelihood of detection (D). Level 3 represents the
18 various alternatives, which are all the fifteen failure modes.




Figure 4: Membership function plot for Occurrence. R: Remote, L: Low, M: Moderate, H: High, VH; Very High.




Figure 5: Membership functions for severity linguistic terms. N: None, VMN: Very minor, MN: Minor, VL: Very Low, L: Low, M: Moderate, H: High, VH; Very High, HWW: hazardous with warning; HWOW: Hazardous without warning.




Figure 6: Membership functions for Detection linguistic terms. AC: Almost certain, Very Low, L: Low, M: Moderate, MH: Moderately high, H: High, VH; Very High, R: Remote, VR: Very remote, AU: Absolutely uncertain.




Figure 7: Comparison of fuzzy synthetic extents.